Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

$12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securitiesPYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal date of September 7, 2025Topline results from RISE UP Phase 3 trial of mitapivat in sickle cell disease on track by year-end with potential U.S. commercial launch in 2026Dosed first patient in the tebapivat Phase 2 sickle cell disease trial and received IND clearance for AG- ...